﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Health Policy</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Health Policy"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.15.26365505v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.14.26365559v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365127v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26364993v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.08.26365076v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.05.26364804v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364447v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.30.26364434v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.29.26364281v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.24.26363851v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363578v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.23.26363788v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.18.26363058v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.22.26358730v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.27.26358874v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.29.26359233v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.01.26359468v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.03.26359585v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.07.26359950v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.13.26360377v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.17.26360374v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.19.26360842v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.19.26360851v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.23.26361157v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.25.26361308v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.26.26361003v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.28.26361597v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.18.26363419v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.17.26363313v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.15.26365505v1?rss=1">
<title>
<![CDATA[
Cost-Effectiveness of Expanding Housing Access for People Experiencing Homelessness and Opioid Use Disorder in California 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.15.26365505v1?rss=1
</link>
<description><![CDATA[
People experiencing homelessness (PEH) have substantially lower quality-adjusted life expectancy and substantially higher healthcare spending compared to housed populations. California has the largest population of PEH in the United States, and an estimated ten percent of PEH have co-occurring opioid use disorder (OUD). We developed a lifetime, individual-level microsimulation of the 18,928 PEH with OUD in California to evaluate the health and economic effects of expanding access to housing through a Housing First approach, which does not require OUD treatment or abstinence. Increases in permanent housing and shelter access were based on Los Angeles County's Measure A goals, and we accounted for both housing and healthcare costs. Expanding housing access increased mean age at death by 0.34 years, reduced fatal overdoses for the cohort by 39, and produced an incremental cost-effectiveness ratio of $31,083 per quality-adjusted life-year gained, well below conventional willingness-to-pay thresholds. We provide evidence that housing is a high-value health intervention for PEH with OUD in California. Policymakers should support Housing First programs as part of integrated responses to the intertwined crises of homelessness and opioid use.
]]></description>
<dc:creator><![CDATA[ Ling, Y., Tsung, S., Alarid-Escudero, F., Goldhaber-Fiebert, J. D., Brandeau, M. L., Reitsma, M. B. ]]></dc:creator>
<dc:date>2026-10-19</dc:date>
<dc:identifier>doi:10.64898/2026.10.15.26365505</dc:identifier>
<dc:title><![CDATA[Cost-Effectiveness of Expanding Housing Access for People Experiencing Homelessness and Opioid Use Disorder in California]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-19</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.14.26365559v1?rss=1">
<title>
<![CDATA[
Social Needs Z Codes and Subsequent Acute Care Across 21 U.S. Health Systems 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.14.26365559v1?rss=1
</link>
<description><![CDATA[
Health systems increasingly record ICD-10 Z59 social-needs codes for housing, food, transportation, and related hardship to trigger referrals, report quality, and adjust risk. However code documentation occurs at varying rates and no study has separated what the code says about a patients hardship from what it says about being documented at all. Using a linked electronic health record and claims corpus covering 4.95 million patients in 21 identifiable health systems, we matched 26,153 adults with a first outpatient Z59 code to similar uncoded patients and, as a negative control, repeated the entire design around an administrative code. Coding ranged from 1 percent to 24 percent of patients across systems and remained highly variable after adjustment for patient mix. A hardship code was associated with 67% (95% CI=1.61, 1.74) more emergency department (ED) visits and 43% (95% CI=1.38, 1.49) more hospital admissions in the next year (62 versus 49 of every 100 patients with any acute event). The administrative-code reproduced 46 percent of the Z59 association for ED visits and 70 percent for admissions. In the five systems with the most complete stay dates, no hardship-specific admission excess was detectable. Homelessness codes forecast two and a half times the ED visit rate. At national planning prices, excess emergency and preventable hospital care totaled roughly $2,000-$2,500 per coded patient-year ($2,516 base scenario; about $1,100 under an exploratory assumed-discount scenario (not an estimate of hardship-attributable spending)), with the largest emergency burden among Medicaid patients. The Z code added no increment to clinical and utilization-based risk prediction models in any system.
]]></description>
<dc:creator><![CDATA[ Lobelo, F., Durieux, J., Ashoo, S., Colovos, C. ]]></dc:creator>
<dc:date>2026-10-16</dc:date>
<dc:identifier>doi:10.64898/2026.10.14.26365559</dc:identifier>
<dc:title><![CDATA[Social Needs Z Codes and Subsequent Acute Care Across 21 U.S. Health Systems]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-16</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365127v1?rss=1">
<title>
<![CDATA[
Functionality status and drivers of non-functionality of the standardised laboratory analysers in Tanzania mainland: Findings from a National Equipment Harmonisation and Standardisation Mapping Exercise 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365127v1?rss=1
</link>
<description><![CDATA[
IntroductionReliable, well-maintained laboratory equipment is essential for timely, accurate and reliable laboratory results for patient care, surveillance, and health system resilience. Tanzania implemented the Standard Medical Laboratory Equipment Guideline (SMLEG-2018) to harmonise procurement and improve efficiency across a tiered laboratory system and network. However, equipment functionality gaps remain a critical challenge for healthcare delivery. This study determined the functionality status of standardised laboratory analysers in Tanzania mainland and identified the drivers of non-functionality.

MethodsWe conducted a facility-based cross-sectional study to identify the causes of non-functionality of standardised chemistry, haematology, and urine analysers across mainland Tanzania. We assessed 3,044 analysers and used Pareto analysis to identify the primary drivers of non-functionality.

ResultsOf the 3,044 standardised analysers assessed, 987 (32.4%) chemistry 1,308 (43.0%) haematology, and 749 (24.6%) urine) assessed; 397 (13.0%) were non-functional. Proportionally, urine analysers were the most non-functional (n=176/749, 23.5%), followed by chemistry (n=135/987, 13.7%), and haematology (n=86/1308, 6.6%) analysers, p<0.001. Urine analysers had significantly higher non-functional equipment (23.5%), followed by Chemistry analysers (13.7%), than Haematology analysers (6.6%), p<0.001. Equipment breakdown was the leading cause of non-functionality, accounting for 70.9% (61/86), 70.5% (124/176) and 60.0% (81/135) of the non-functional haematology, urine and chemistry analysers, respectively, among all causes identified for each analyser type.

ConclusionAlthough the SMLEG 2018 implementation identified broad coverage of functional standardised laboratory equipment, persistent equipment breakdowns of more than 10% highlight a systemic, concerning gap that requires immediate corrective action to sustain high performance. Strengthening preventive maintenance, timely repair services and sustainable equipment lifecycle planning is critical to sustaining quality laboratory services for robust preventive and curative care.
]]></description>
<dc:creator><![CDATA[ Torokaa, P., Makala, R., Kitukulu, J. D., Shija, E. M., Kelly, M. E., Kwavava, G. E., Mkala, R. S., Paul, I. G., Jidayi, M. N., Massawe, R. Y., Ocheng, D. M., Ng'ola, P. M., Panga, O. D., Matata, L. F., Karoli, L. N., Kyalo, A., Magesa, A. S., Mtebe, M., Joachim, A., Moremi, N. ]]></dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365127</dc:identifier>
<dc:title><![CDATA[Functionality status and drivers of non-functionality of the standardised laboratory analysers in Tanzania mainland: Findings from a National Equipment Harmonisation and Standardisation Mapping Exercise]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26364993v1?rss=1">
<title>
<![CDATA[
Estimating Physician-Patient Face-to-Face Time Using Electronic Health Record Audit Logs 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26364993v1?rss=1
</link>
<description><![CDATA[
ImportanceThe Medicare Physician Fee Schedule values ambulatory services using survey-based estimates of physician time, a costly process vulnerable to inaccuracy. EHR audit logs are passively and universally collected and likely meet the American Medical Association Relative Value Scale Update Committee (AMA RUC) Extant Database Standards for alternative data to inform service valuation estimates. However, audit logs validity for estimating face-to-face time, a core component of many of the most used procedural codes, is unknown.

ObjectiveTo assess whether EHR audit logs can facilitate accurate estimation of physician-patient face-to-face time during ambulatory visits.

DesignSingle-site validation study pairing EHR audit logs with direct audio/video recordings of ambulatory primary care visits (reference standard). We assessed agreement between audit-log estimates and recorded visit duration with Bland-Altman analysis and mean absolute error.

SettingUniversity of Pennsylvania Observer data repository, a multi-modal database of ambulatory visits to Penn Medicine primary care clinics including video and audio recordings, transcripts, clinical EHR data, and EHR audit-log data.

Participants75 visits from 12 physicians with data collected between August 2023 and February 2025.

ExposuresA rule-based algorithm estimated face-to-face time via clusters of physician EHR activity relative to patient check-in time. Inactivity thresholds were applied to differentiate intraservice time with no EHR activity (e.g., a physical exam) from the end of a visit, with longer thresholds used for longer visits.

Main Outcomes and MeasuresDuration of recorded face-to-face visit time.

ResultsRecorded face-to-face time averaged 31.6 minutes (SD, 13.9). The audit-log estimator was unbiased (mean bias: -0.63 minutes; 95% CI: -6.0 to 2.6; mean absolute error: 9.0 minutes) and estimated face-to-face time within approximately 2% (38 seconds) of the recorded visit time with no proportional bias (slope: 0.13; P = .25). The 95% limits of agreement were -25.7 to 24.4 minutes, and 37% of estimates fell within 10% of recorded duration.

Conclusions and RelevanceIn this validation study, EHR audit logs recovered unbiased estimates of ambulatory face-to-face time. Larger-scale studies are required to verify generalizability, but EHR audit logs offer a scalable means to improve the rigor of retrospective physician work relative value unit estimation. This study represents a first step in a potential paradigm shift for measuring components of the fee schedule across procedures, settings, and provider types.

Key PointsO_ST_ABSQuestionC_ST_ABSCan electronic health record (EHR) audit log data be used to accurately estimate physician-patient face-to-face time for ambulatory visits?

FindingsIn this single-site validation study of 75 ambulatory visits with paired visit recordings, a combined rule-based estimation strategy recovered average face-to-face time to within approximately 2% of recorded duration (mean bias: -38 seconds), with no significant proportional bias, although visit-level agreement was modest.

MeaningUniversally and passively collected EHR audit log data may provide a scalable, low-bias source for estimating discrete components of physician service time to inform fee-schedule valuation.
]]></description>
<dc:creator><![CDATA[ Apathy, N. C., Cross, D. A. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26364993</dc:identifier>
<dc:title><![CDATA[Estimating Physician-Patient Face-to-Face Time Using Electronic Health Record Audit Logs]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.08.26365076v1?rss=1">
<title>
<![CDATA[
Bridging medicine access gaps through cross-national market linkage in South Korea and Italy: a conceptual case 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.08.26365076v1?rss=1
</link>
<description><![CDATA[
BackgroundMedicine shortages are monitored within national borders, but complementarity across national markets is poorly characterised.

ObjectiveTo characterise medicines supplied through South Koreas national access programme and to quantify this complementarity between South Korea and Italy.

MethodsIn this cross-sectional study, we linked shortage records from the Italian Medicines Agency and Korean Ministry of Food and Drug Safety, Korea Orphan and Essential Drug Center supply notices, and national reimbursement lists. The primary outcome was the proportion of shortage configurations with a reimbursed counterpart in the partner country, identified by normalised ingredient, pharmaceutical form, and route, and not recorded as withdrawn or in shortage. The primary analysis covered Jan 1-June 30, 2026, and the secondary analysis covered 2023-26.

ResultsAmong 341 formulations supplied through the Korean national access programme, 242 (71.0%) lacked domestic marketing authorisation at first observed supply or were supplied after market withdrawal. Of 338 Italian shortage configurations in the first half of 2026, 228 (67.5%) had an available reimbursed Korean counterpart; over 2023-26, 332 of 549 (60.5%) did. Conversely, 27 of 47 Korean configurations (57.4%) had such an Italian counterpart; over 2023- 26, 93 of 184 (50.5%) did. In both directions, ingredients on EU critical or Korean essential medicine lists more often had a cross-border match than unlisted ingredients.

ConclusionsAbout half of shortage or access-gap medicines had a potentially available reimbursed counterpart in the other country. Cross-national linkage of medicine data may help identify potential counterparts, although these require regulatory, clinical, and procurement review.

Research in contextO_ST_ABSWhat is already known about the topic?C_ST_ABSStudies have mainly compared shortage patterns or management across countries or described importation and information sharing as responses. A 2025 US analysis found that, for about two-thirds of generic sterile injectables in shortage with three or fewer US manufacturers, a version was approved in peer countries. We found no study that linked national shortage records to a partner countrys reimbursement market while accounting for withdrawals and concurrent shortages.

What does this study add to the literature?In the first half of 2026, about two-thirds of Italian and more than half of Korean shortage or access-gap configurations had an available reimbursed counterpart abroad, and critical or essential medicines more often had a cross-border match. Most medicines supplied through South Koreas national access programme lacked domestic marketing authorisation at first supply or were supplied after market withdrawal.

What are the policy implications?Linking national registers can identify candidate counterparts across borders, but each requires product-level regulatory and procurement review and an institution able to act on the resulting information. Wider application would require standardised reporting of ingredient, form, route, and shortage date.
]]></description>
<dc:creator><![CDATA[ Sohn, M., Musazzi, U. M. ]]></dc:creator>
<dc:date>2026-10-11</dc:date>
<dc:identifier>doi:10.64898/2026.10.08.26365076</dc:identifier>
<dc:title><![CDATA[Bridging medicine access gaps through cross-national market linkage in South Korea and Italy: a conceptual case]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-11</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.05.26364804v1?rss=1">
<title>
<![CDATA[
Hypertension disease natural history and healthcare utilization when treatment guidelines do not account for race 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.05.26364804v1?rss=1
</link>
<description><![CDATA[
ObjectiveTo estimate the impact of removing race-adjusted antihypertensive treatment recommendations for Black adults on health outcomes, healthcare utilization, and racial/ethnic disparities.

Materials and methodsA discrete-time state-transition microsimulation model of hypertension natural history and health system utilization was developed to simulate lifetime trajectories among 100,000 non-Hispanic Black and non-Hispanic white 40-year-old adults. We evaluated the effect of removing race-adjusted antihypertensive treatment recommendations under two scenarios: one assuming racial heterogeneity in treatment effectiveness, reflecting evidence behind prior race-specific guidelines, and the other assuming no racial heterogeneity. Our main outcomes included life expectancy, cumulative incidence and duration of hypertension, and blood pressure control with antihypertensive treatment.

ResultsUnder assumptions of heterogeneous treatment effectiveness by race, guidelines without race adjustment decreased life expectancy among non-Hispanic Black adults by 0.4 years, increasing the life expectancy gap with non-Hispanic white adults from 4.1 to 4.5 years. Hypertension control among non-Hispanic Black adults also worsened. Years with uncontrolled hypertension increased by 0.8 years, widening the disparity with non-Hispanic white adults from 1.7 to 2.5 years. Assuming no racial heterogeneity, these effects were diminished: life expectancy decreased by 0.1 years and years with uncontrolled hypertension increased by 0.2 years, less than one-half and one-quarter of the effects observed under assumptions of heterogeneous treatment effectiveness by race.

DiscussionThe potential effects of removing race-adjusted antihypertensive treatment guidelines depended on assumptions of racial heterogeneity in treatment effectiveness.

ConclusionOur findings highlight the importance of understanding drivers of previously observed racial differences when considering modifying antihypertensive treatment guidelines.
]]></description>
<dc:creator><![CDATA[ Cusick, M. M., Barrett, M., Alarid-Escudero, F., Goldhaber-Fiebert, J. D., Rose, S. ]]></dc:creator>
<dc:date>2026-10-07</dc:date>
<dc:identifier>doi:10.64898/2026.10.05.26364804</dc:identifier>
<dc:title><![CDATA[Hypertension disease natural history and healthcare utilization when treatment guidelines do not account for race]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364447v1?rss=1">
<title>
<![CDATA[
Safety-Relevant Biomedical Machine Learning Should Adopt Stability-First Reporting 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364447v1?rss=1
</link>
<description><![CDATA[
Biomedical Machine Learning (ML) is increasingly evaluated through Independent and Identically Distributed (IID) benchmarks, even when deployment involves irregular observation, missingness, distribution shift, and high failure costs. This position paper argues for a stability-oriented reporting standard for safety-relevant biomedical ML. The central requirement is not a specific model class or optimizer, but auditable evidence: performance should be reported under clinically plausible perturbations such as thinning, timestamp jitter, bursty missingness, channel dropout, and Signal-to-Noise Ratio (SNR) shift. When authors invoke training-stability diagnostics, those diagnostics should be hazard-linked: their assumptions, operational meaning, and relationship to stress-test degradation should be stated explicitly. We use controlled mechanism probes to illustrate two hazards that IID scores can hide: observation-process dependence under irregular sampling, and perturbation sensitivity associated with high-curvature training regimes such as Edge of Stability (EoS). We do not propose Neural ODEs, continuous-time models, Sharpness-Aware Minimization (SAM), or EoS metrics as default prescriptions. Instead, we propose a minimum reporting standard that makes robustness claims testable and supports escalation to more complex modelling or optimization only when stress tests justify the cost.
]]></description>
<dc:creator><![CDATA[ Zainal, Z. A., Kavehei, O., Aguilar, I., Herbozo Contreras, L. F., Huang, Z. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364447</dc:identifier>
<dc:title><![CDATA[Safety-Relevant Biomedical Machine Learning Should Adopt Stability-First Reporting]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.30.26364434v1?rss=1">
<title>
<![CDATA[
Model-based evaluation of an infant HPV prophylactic vaccination program in Nigeria 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.30.26364434v1?rss=1
</link>
<description><![CDATA[
BackgroundNigeria introduced single-dose HPV vaccination for girls aged 9-14 in 2023, reaching approximately 60% aggregate coverage by 2025. While an important achievement, this remains short of the 90% coverage called for under the WHOs 90-70-90 cervical cancer elimination targets, and further scale-up depends on reaching out-of-school girls. In this study we used a model of HPV transmission in Nigeria to quantify the residual cervical cancer burden under continued adolescent delivery, assess how additional screening scale-up and equity assumptions modify it, and identify the effective coverage requirements for an infant HPV vaccination program to be non-inferior to the existing adolescent strategy.

MethodsWe used HPVsim, an agent-based microsimulation calibrated to Nigerian sexual behavior, HPV prevalence, and cervical cancer incidence, to project new cervical cancer cases and age-standardized incidence over 2025-2100 under scenarios which vary vaccination delivery mode (status-quo adolescent, WHO 90-70-90 adolescent scale-up, and 60/75/90% infant delivery), screening coverage (opportunistic 15% vs. scaled 70% aggregate), and the degree to which primary school completion correlated with vaccination (odds ratio 1 vs. 5) and with screening (odds ratio 1 vs. 3). Infant delivery scenarios were run at hypothetical effective-vaccine-efficacy-at-exposure values of 50%, 70%, and 95% -- scenario inputs bracketing the plausible waning range, not evidence-based estimates of infant vaccine performance (no HPV vaccine trial has enrolled anyone below age 10). Each scenario was run at 50 replicates (10 calibration draws x 5 seeds); reported outcomes are the median across replicates and uncertainty ranges are interquartile (25th-75th percentile).

ResultsContinuation of Nigerias current adolescent program is projected to avert 1.82 million cervical cancer cases (IQR 1.65-1.90 million; 95% UI 1.39-2.02 million) over 2025-2100 (a 53% reduction relative to no vaccination, IQR 51-55%; 95% UI 46-58%), with age-standardized incidence falling from 19.7 to 7.8 per 100,000 by 2100. However, 82% of the near-term (2025-2075) burden is projected to fall on the pre-2015 birth cohort, i.e. women already beyond the vaccination target age, leaving approximately 945,000 residual cases (IQR 905K-1.00M; 95% UI 835K-1.14M) in this cohort. Scaling up screening to WHO targets was estimated to avert a further [~]387K cases (IQR 331-424K; 95% UI 269-515K), roughly 25% of the residual burden; results were about 6-8% better if the scale-up instead reached all women equitably regardless of education. Under a hypothetical scenario of infant vaccination at 90% coverage and 95% effective vaccine efficacy at exposure (matching adolescent-age performance), outcomes were comparable to full WHO adolescent scale-up (49% vs. 54% reduction in vaccine-targetable cohort cancers), but under a hypothetical 50% effective efficacy at Nigerias DTP3-anchored 62% coverage the strategy averted only a fraction of these cancers.

ConclusionsThe near-term cervical cancer burden in Nigeria is dominated by cohorts vaccination cannot reach; scaling screening for them is the more consequential lever over the coming three decades and rests on established evidence. Findings on infant HPV delivery are exploratory and hypothesis-generating: they depend on three unverified empirical prerequisites - infant HPV vaccine immunogenicity in the first months of life, durability of protection across the [~]15-25-year interval to peak HPV exposure, and coverage achievable through Nigerias routine childhood immunization platform - and should not be read as a basis for any policy recommendation contingent on infant HPV delivery until those prerequisites are established.
]]></description>
<dc:creator><![CDATA[ Stuart, R. M., Umeh, I., Gill, C., Cohen, J. A. A. ]]></dc:creator>
<dc:date>2026-10-02</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.26364434</dc:identifier>
<dc:title><![CDATA[Model-based evaluation of an infant HPV prophylactic vaccination program in Nigeria]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.29.26364281v1?rss=1">
<title>
<![CDATA[
Conditional Optimism and Systemic Constraints: Healthcare Provider Perceptions of AI in Safety-Net Settings Using a Mixed-Methods Vignette Approach 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.29.26364281v1?rss=1
</link>
<description><![CDATA[
As health AI tools enter clinical spaces, how they are perceived by providers in safety-net environments shapes whether their benefits reach underserved populations. We examined the degree and drivers of healthcare providers trust in health AI, whether that trust moderates perceived benefits for safety-net populations, and how providers balance benefit against concern across four specific hypothetical AI tools. We used a two-study mixed-methods design: 18 semi-structured interviews with healthcare practitioners and research leaders, followed by a survey of 229 Texas healthcare providers incorporating four vignettes describing hypothetical AI tools, each rated for appeal and concern and followed by open-ended explanation. Responses were thematically coded and stratified by self-reported trust in health AI (47.6% high trust, 52.4% low trust). Low-trust respondents most often cited building trust (50.5%) and data bias and accuracy (33.0%) as drivers of their current trust level, while high-trust respondents more often cited efficient and effective care (23.5% vs. 3.7% low-trust, p<0.001) and accuracy of data (11.8% vs. 1.8% low-trust, p=0.004); concerns about data security, governance, and the need for human oversight were raised at similar rates by both groups. When asked how AI could specifically benefit safety-net populations, both groups converged on expanding access to care (45.9% each), and none of 25 benefit-related codes differed significantly by trust group. Across all four vignettes, mean appeal ratings exceeded mean concern ratings, and high-trust providers rated every tool as more appealing and, for three of four tools, less concerning, without changing which tool ranked where relative to others. Providers exhibit conditional optimism: support is contingent on governance, human oversight, and context-sensitive implementation rather than on the technology itself. Realizing AIs promise for safety-net populations will require human-in-the-loop models, localized implementation strategies, community-informed design, and engaging providers directly in policy design and tool development.

Author SummaryArtificial intelligence is increasingly built into the everyday tools that healthcare workers use, but whether it actually helps the patients who need the most support depends on what those workers think of it and how much they trust it. We talked with 18 healthcare workers and researchers, then surveyed 229 healthcare providers across Texas, many of whom work in clinics and hospitals that serve low-income and rural communities. About half of the providers we surveyed trusted health AI and half did not. Providers who trusted AI less pointed to a need to build trust and worries about biased or inaccurate data; providers who trusted it more pointed to gains in efficient, accurate care. Both groups agreed, in similar numbers, that AIs biggest promise for underserved patients is expanding access to care, and neither group described that promise differently from the other. When we showed providers four realistic AI tools, all of them found more to like than to worry about. Our findings suggest that providers are not simply for or against health AI. Their support depends on whether AI is deployed with real human oversight, sound governance, and attention to the specific setting where it is used.
]]></description>
<dc:creator><![CDATA[ Purohit, I., Kammer-Kerwick, M., Spandikow, E., Pogue, G., Watkins, S. C. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.26364281</dc:identifier>
<dc:title><![CDATA[Conditional Optimism and Systemic Constraints: Healthcare Provider Perceptions of AI in Safety-Net Settings Using a Mixed-Methods Vignette Approach]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.24.26363851v1?rss=1">
<title>
<![CDATA[
Age-Standardized Comorbidity Prevalence of Cardiometabolic Conditions and Socioeconomic Inequalities in Hong Kong: A District Comparison 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.24.26363851v1?rss=1
</link>
<description><![CDATA[
BackgroundHypertension (HTN) and Type 2 diabetes mellitus (T2DM) are leading drivers of the global cardiometabolic disease burden and major contributors to preventable morbidity and mortality. In Hong Kong, where population ageing and lifestyle-related risk factors are increasingly prevalent, both conditions and their complications pose substantial challenges to the healthcare system. Although territory-wide prevalence figures are available, small area district-level evidence on the burden of these diseases and their associated complications remains limited. Disparities are likely due to heterogeneity in demographic composition, socioeconomic status, and primary care accessibility across Hong Kongs eighteen administrative districts. There is also a lack of accessible, age-adjusted, district-level disease visualization in Hong Kong.

ObjectivesThis study estimates the age-standardized prevalence rates (ASPR) of HTN, T2DM, and their associated complications across the eighteen districts of Hong Kong, formally evaluate the statistical significance of inter-district disparities, and rank the districts according to disease burden to inform place-based health planning.

MethodsThis study analyzed the prevalence of chronic diseases from 2014 to 2023 in 18 districts among an adult cohort aged [&ge;]35 years using data collected from the Hong Kong Hospital Authority (HA) electronic health records, using the International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes, the International Classification of Primary Care (ICPC) codes, and the disease flags to identify diseases. Sample weights are used to reflect the total population. HTN, T2DM, and their major complications were identified according to standardized diagnostic criteria. ASPR were calculated for each district with the WHO World Standard Population as the standard. Inter-district disparities in disease prevalence were assessed using Cochrans Q test, with statistical significance set at P <0.05. The slope index of inequality (SII) was also used to analyze the socioeconomic inequality between districts. Districts were subsequently ranked according to their ASPR for each condition to identify high-burden and low-burden areas.

Results1,756,521 patients (52.71% females) contribute 9,906,729 patient-years from 2014 to 2023. Substantial inter-district variation and increasing trend were observed in the ASPR of HTN, T2DM, and their complications. The weighted ASPR of HTN varied by 27.3% from 46,701 (95% CI: 45,691-47,711) per 100,000 population in Tsuen Wan district to 59,445 (95% CI: 58,759-60,130) per 100,000 population in Yuen Long district, and the weighted ASPR of T2DM ranged from 20,464 (Tsuen Wan, 95% CI: 19,803-21,124) per 100,000 population to 28,275 (Yuen Long, 95% CI: 27,792-28,758) per 100,000 population across the districts in 2023. All diseases showed district disparities (all P <0.05). Cochrans Q test demonstrated statistically significant disparities across districts and showed no convergence through the period. The SII test also showed the most serious inequality exists in HTN, with the lower socioeconomic position districts have more burden.

ConclusionSignificant geographic disparities exist in the prevalence of HTN, T2DM, and their complications across Hong Kongs eighteen districts. These findings highlight the need for district-specific public health strategies, equitable allocation of primary care resources, and targeted chronic disease prevention and management programs in high-burden areas.
]]></description>
<dc:creator><![CDATA[ Zhou, J., Liu, Z., Cai, Y., Wu, Q., Bishai, D. M. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.24.26363851</dc:identifier>
<dc:title><![CDATA[Age-Standardized Comorbidity Prevalence of Cardiometabolic Conditions and Socioeconomic Inequalities in Hong Kong: A District Comparison]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363578v1?rss=1">
<title>
<![CDATA[
Community Perspectives on PCB Exposure, Health Risks, and Exposure-Reduction Strategies in Guanica, Puerto Rico, Home to a Newly Designated Superfund Site 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363578v1?rss=1
</link>
<description><![CDATA[
BackgroundGuanica, Puerto Rico, has one of the highest concentrations of environmental polychlorinated biphenyls (PCBs). This PCB contamination coupled with persistent poverty, population loss, and repeated environmental disasters has taken a heavier toll on Guanica community. Our environmental sampling has documented high levels of PCBs in sediment, air and fish, but far less is known about how residents themselves understand exposure, interpret health risk, and weigh contamination against the other pressures of daily life.

MethodsWe used a qualitative descriptive design nested within the larger HELP Study. This paper presents the final analysis of all qualitative data collected in Guanica: ten sessions comprising five focus groups and five interviews with fishermen (N = 31), conducted between November 2024 and October 2025 in familiar community settings. Sessions followed a semi-structured guide translated from English to Spanish and back-translated for accuracy. Recordings were transcribed in Spanish, verified against the audio, and analyzed in NVivo using codebook-style thematic analysis; three bilingual researchers coded collaboratively and resolved disagreements by consensus.

ResultsFive themes emerged from our analysis concerning how residents and fishermen understand and navigate PCB contamination: (1) perceived community decline shapes how residents prioritize environmental risks; (2) limited knowledge, misinformation, and communication gaps affect understanding of PCB contamination; (3) cancer concerns are high, but links to PCB exposure remain unclear; (4) PCB contamination is seen as a threat to livelihoods, especially fishing and tourism; and (5) deep mistrust and a desire for accountability influence perceptions of environmental interventions. Participants described contamination not as an isolated hazard but as one strand of a longer history of economic decline, disaster, and institutional neglect.

ConclusionsSocial, economic, and environmental conditions together shape how Guanica residents perceive contamination of their environment. Meaningful progress requires sustained community involvement, support for local initiatives, development of a Community Health Worker program, and expanded partnerships with local institutions and schools to close communication gaps and promote long-term resilience to address the health effects of PCB contamination in Guanica.
]]></description>
<dc:creator><![CDATA[ Acuna, N., Ortiz, J., Rosario, N. E., George, S. S., Gonzalez, S., Carrasquillo, O., Domenech, L. T., Ortiz, A., Coredor-Cardona, N., Cruz, L. A., Ramos, S. R., Silva, M. G., Rodriguez, J. A., Kumar, N. ]]></dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363578</dc:identifier>
<dc:title><![CDATA[Community Perspectives on PCB Exposure, Health Risks, and Exposure-Reduction Strategies in Guanica, Puerto Rico, Home to a Newly Designated Superfund Site]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.23.26363788v1?rss=1">
<title>
<![CDATA[
Exploring possible point-of-sale restrictions for vapes and nicotine pouches: cross-sectional surveys with adults and adolescents in the UK 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.23.26363788v1?rss=1
</link>
<description><![CDATA[
IntroductionWithin the Tobacco and Vapes Act 2026, the UK Government is considering restricting retail displays of vaping and other nicotine products to discourage youth uptake. We explored how adult nicotine users and adolescents responded to conventional and restricted displays.

MethodsTwo UK-wide cross-sectional online surveys were conducted April-June 2026, with current and former adult nicotine users (n=2,851), and adolescents (11 17 years; n=2,123). Participants rated images of vape and nicotine pouch point-of-sale (POS) displays (two conventional, two restricted) across 10 items. Other measures included demographics, smoking/vaping/nicotine pouch use, vaping susceptibility, and product choice.

ResultsRatings of two conventional POS images were consistently favourable. Two restricted POS images were almost exclusively rated unfavourably. GEE analyses, controlling for demographics and behaviour, indicated that a display with standardised white packs (versus a conventional display) consistently had lower odds of favourable ratings (adults range:0.13-0.31; adolescents range:0.11-0.32). A fully covered display had even lower odds of favourable ratings on all items (adults range:0.06-0.19; adolescents range:0.05-0.10). Presented with hypothetical restricted displays, most adults using nicotine remained consistent with their product choice. Favourable ratings of conventional displays were positively associated with adolescents vaping susceptibility. Those favourably rating a large, branded display were more likely to be susceptible than those giving unfavourable/neutral ratings (AOR=2.73, 95%CI [2.16-3.45] p<0.001). No association was found between favourable ratings of restricted displays and susceptibility.

ConclusionRestricting POS displays could reduce positive messaging around vaping and adolescent susceptibility. The potential impact of restrictions on adult users perceptions of harm and accessibility should be considered.

What is already known on this topicO_LIOpen point-of-sale (POS) displays are an effective marketing tool which increase attention, communicate positive product attributes, influence social norms, and drive sales.
C_LIO_LIWhile evidence demonstrates the impact of open and banned POS display of tobacco, there is a lack of research on how adults and adolescents respond to conventional and restricted POS displays of vapes or other nicotine products,
C_LI

What this study addsO_LIAdults and adolescents almost exclusively rated conventional POS images favourably, and restricted POS images, unfavourably.
C_LIO_LIFavourable ratings of conventional displays were positively associated with adolescents vaping susceptibility, while no association was found between favourable ratings of restricted displays and susceptibility.
C_LI

How this study might affect research, practice or policyO_LIRestricting POS displays may reduce positive vaping messages and adolescents susceptibility to vaping,
C_LI
]]></description>
<dc:creator><![CDATA[ MacKintosh, A. M., Best, C., Moodie, C., Angus, K., Alexandrou, G., Ford, A. ]]></dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.26363788</dc:identifier>
<dc:title><![CDATA[Exploring possible point-of-sale restrictions for vapes and nicotine pouches: cross-sectional surveys with adults and adolescents in the UK]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.18.26363058v1?rss=1">
<title>
<![CDATA[
Trends and differences in breast cancer mortality by race, region and age among Brazilian women, 1996-2024: a nationwide ecological study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.18.26363058v1?rss=1
</link>
<description><![CDATA[
ObjectivesTo quantify the demographic contribution to Brazils rising number of breast cancer deaths and compare mortality trends by region and race/skin color.

Study designNationwide, population-based ecological time-series study.

MethodsDeaths from breast cancer (ICD-10 C50) in the Brazilian Mortality Information System, 1996-2024, were analysed. Crude rates use two denominators, the whole female population and women aged 20 and over. Age-standardized rates used the 2024 IBGE projection and, by race/skin color, Census populations for 2010 and 2022. Trends used weighted log-linear regression with BIC-selected joinpoints, and deaths were decomposed by the Das Gupta method.

ResultsDeaths rose from 7,085 (1996) to 20,849 (2024). Over 2000-2024 the age-standardized rate rose from 11.4 to 14.3 per 100,000 women, with one joinpoint at 2017 (average annual percent change +0.87%, 95% CI 0.77 to 0.96). Growth and ageing accounted for 74.3% of the 12,542 additional deaths at ages 20 and over. Standardized rates rose in every region, fastest in the North (+3.09%/year) and slowest in the Southeast (+0.24%/year), narrowing the highest-to- lowest ratio from 2.67 to 1.38. White women had the highest age-standardized rate at both censuses (2022: 15.96 versus 12.28 and 11.48 per 100,000), Brown women had the larger increase (ratio of relative changes 1.20, 1.13 to 1.26).

ConclusionsPopulation growth and ageing accounted for most of the increase in the number of recorded breast cancer deaths at ages 20 and over. Regional differences in level narrowed, White women had the highest age-standardized rates at both censuses and Brown women the larger increase.
]]></description>
<dc:creator><![CDATA[ Zuffo Yabrude, A. T., Souza Reis, L. C., Saragossa Zafalon, A. E., Fish Araujo de Albuquerque, C., Del Fiol Manna, E. ]]></dc:creator>
<dc:date>2026-09-23</dc:date>
<dc:identifier>doi:10.64898/2026.09.18.26363058</dc:identifier>
<dc:title><![CDATA[Trends and differences in breast cancer mortality by race, region and age among Brazilian women, 1996-2024: a nationwide ecological study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.22.26358730v1?rss=1">
<title>
<![CDATA[
Systemic and structural barriers to effective infection prevention and control practices in a teaching and referral hospital in Kenya: A qualitative study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.22.26358730v1?rss=1
</link>
<description><![CDATA[
BackgroundHealthcare-associated infections (HAIs) are a leading adverse event in healthcare delivery. Despite Kenyas robust National Infection Prevention and Control (IPC) Policy and Strategic Plan, a profound policy-to-practice gap persists at the institutional level. This study explored context-specific structural, behavioral, and administrative barriers hindering IPC implementation at a public referral hospital to inform localized policy tailoring.

MethodsWe conducted a cross-sectional qualitative study at a level V teaching and referral hospital in Kenya. Seven key informant interviews were held with five IPC committee members/providers and two departmental managers. Data from audio recordings and field notes were transcribed, translated, and analyzed via thematic content analysis using QSR NVivo V.12.

ResultsSeven major themes emerged: (1) IPC Training and Knowledge Retention, (2) Workforce Strain and Triaging of IPC, (3) Resource Scarcity and a Disabling Environment, (4) The Community-Hospital Interface, (5) Governance and Policy-to- Practice Lag, (6) IPC Surveillance and Monitoring, and (7) Behavioral Drivers (Attitude, Ignorance, Accountability). Financial and human resource constraints directly undermine continuous medical education, workforce ratios, WASH infrastructure functionality, and the local adaptation of national guidelines.

ConclusionA substantial policy-to-practice gap persists at the facility level due to severe structural, resource, and behavioral constraints. To bridge this gap, hospital leadership must transition from reactive crisis management to proactive, continuous medical education and sustainable WASH infrastructure development. Effective IPC implementation requires national frameworks to be dynamically adapted and tailored to the operational realities and resource limitations faced by frontline healthcare workers.
]]></description>
<dc:creator><![CDATA[ Ndwandwe, S. V., Nyanjui, A. W., Ndebele, L., Kimani, R., Ngethe, J., Wamaitha, N., Nduta, C., Njoroge, G. G., Mbugua, S. M., Gitaka, J. ]]></dc:creator>
<dc:date>2026-07-29</dc:date>
<dc:identifier>doi:10.64898/2026.07.22.26358730</dc:identifier>
<dc:title><![CDATA[Systemic and structural barriers to effective infection prevention and control practices in a teaching and referral hospital in Kenya: A qualitative study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.27.26358874v1?rss=1">
<title>
<![CDATA[
Global Programmatic Survey on Governance and Surveillance of Nontuberculous Mycobacteria 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.27.26358874v1?rss=1
</link>
<description><![CDATA[
BackgroundNontuberculous mycobacteria (NTM) are clinically important pathogens but often weakly positioned within health systems, with unclear institutional ownership, variable notification arrangements, and limited surveillance visibility.

MethodsWe conducted a multilingual online survey among programme-facing national and subnational mycobacterial stakeholders from November to December 2025. Using an adaptive hierarchical recruitment strategy, we targeted 217 countries and jurisdictions. One response per programme was requested. We assessed institutionalisation, notification, agenda maturity, thematic discussion priorities, and barriers to action. We also derived relative policy momentum from three urgency domains (diagnostics, clinical management, and surveillance) using within-WHO region hierarchical clustering. Findings were used to develop a heuristic roadmap for staged NTM governance and system visibility.

ResultsWe received 193 programme-level responses, including from subnational jurisdictions, representing 171 of 217 targeted countries (78.8% jurisdictional coverage). NTM institutionalisation status was heterogeneous: 34% reported NTM integration within the NTP, while 37% expressed intents to institutionalise within the NTP in nearest future. Mandatory notification was reported by 21% of programme units, voluntary notification by 10%, and notification under consideration by 24%. NTM appeared to enter policy discussions along a gradient, with clinical management and diagnostics attracting earlier attention than surveillance, training needs, and financing. Globally, pulmonary NTM was discussed more frequently than extrapulmonary disease. Across WHO regions, policy momentum clustering separated programmes into higher and lower profiles, with surveillance consistently being the weakest domain. Financing and lack of epidemiological data were identified as the most actionable barriers. There was broad support for TB-NTM surveillance integration.

ConclusionsNTM governance is heterogeneous and frequently weakly anchored globally. The findings do not support a single universal institutional model; rather, existing mycobacterial platforms may provide pragmatic starting points for improving programme visibility, coordination, and reporting. The proposed heuristic roadmap outlines staged governance options according to burden, capacity, and institutional context.
]]></description>
<dc:creator><![CDATA[ Jain, N., Kuksa, L., Affolabi, D., Munoz, F. E. A., Scappaticcio, A., Pandey, S., Shephard, L., Hasan, R., Guglielmetti, L., Wijnant, G.-J., Andre, E., Rigouts, L., Lorent, N., the NTM Global Policy Study Group ]]></dc:creator>
<dc:date>2026-08-02</dc:date>
<dc:identifier>doi:10.64898/2026.07.27.26358874</dc:identifier>
<dc:title><![CDATA[Global Programmatic Survey on Governance and Surveillance of Nontuberculous Mycobacteria]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.29.26359233v1?rss=1">
<title>
<![CDATA[
Nutri-Score labelling in the out-of-home food sector: evidence on effectiveness from a large, randomised control trial in UK restaurant settings 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.29.26359233v1?rss=1
</link>
<description><![CDATA[
BackgroundOver half of UK adults eat food prepared out-of-home (OOH) weekly and the poor nutritional profile of OOH food contributes to ill health. Nutri-Score is a form of interpretative labelling which assigns food products a value of A (healthiest) to E (least healthy) based on nutritional quality, and inclusion on menus could be a public health policy option to reduce obesity. This is the first real-world Randomised Control Trial to test the effectiveness of Nutri-Score alongside calorie labelling on food menus in UK OOH settings.

MethodsAdult participants (N=672), majority White (80%) female (63%), with a mean age of 47({+/-}18) years, were recruited from the local community to visit OOH food businesses to order, consume, and pay for meals. Data collection days were randomised to be control (calorie labelling) or Nutri-Score (calorie labelling with Nutri-Score). Linear mixed models assessed impacts of labelling condition on perceived effectiveness of menu labelling and nutritional quality of food orders.

FindingsScores for perceived effectiveness of labelling were significantly greater in the Nutri-Score condition compared to control (B = 0.21, p=0.010; 95% CI 0.05, 0.37) and food orders were significantly better nutritional quality, indicated by lower Nutrient Profiling Model scores in the Nutri-Score vs. control condition (B = -0.89, p=0.003; 95% CI -1.48, -0.31).

InterpretationCompared to providing calorie labelling alone, inclusion of Nutri-Score could be an effective policy approach to improve nutritional quality of diet and reduce diet-related disease.

FundingThis research was funded by the Economic and Social Research Council (ESRC;Reference ES/W007932/1).

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSPubMed was searched for all research into Nutri-Score food labelling, published between June 2016 (earliest available result), and February 24, 2026, using the search terms: (((((Nutri-Score)) OR (Nutriscore)) OR (Nutri-Score label*)) OR (Nutriscore label*)) with no language restrictions. The search returned n=354 articles deemed relevant according to title and abstract content. Nutri-Score labelling has been adopted as a front-of-pack food labelling policy in several European countries. Systematic reviews and meta-analyses have explored the impact of Nutri-Score labelling, primarily on food packaging, through both real world and experimental evidence. Findings suggest that Nutri-Score is effective in helping consumers to identify healthier foods, and rank foods in order of healthiness.

Additionally, Nutri-Score labelling is associated with improved nutritional quality of food selection, by facilitating the selection of healthier food choices and the avoidance of less-healthy food choices. However, most studies to date have been conducted in experimental settings, and only n=2 studies have tested Nutri-Score in out-of-home (OOH) settings. The two studies conducted in the OOH food sector were conducted in France and differed in design (e.g., non-randomized). Findings have suggested that Nutri-Score is associated with food choices of greater nutritional quality, although effects may not be consistent across socioeconomic status.

Added value of this studyNo research has examined the effectiveness of Nutri-Score on food choices with a UK population or the impact of Nutri-Score on nutrient consumption (as opposed to purchase or selection). Inclusion of interpretive labelling (i.e., Nutri-Score) for OOH food menus is a potential avenue for national government policy, however research to assess effectiveness and guide implementation of such policy is limited. In the present real-world randomised controlled trial, participants visited an OOH food business in Liverpool city centre and selected a meal from a control menu (calorie labelling only) or a Nutri-Score intervention menu (calorie labelling with Nutri-Score). Primary outcomes of interest were perceived message effectiveness and nutritional quality of meal ordered.

Implications of all the available evidenceThe evidence suggests that Nutri-Score labelling combined with calorie labelling on food menus is perceived to be effective by consumers and may prompt healthier food choices than calorie labelling alone. The inclusion of interpretative nutrition information, such as Nutri-Score, should be considered for OOH settings as a public health policy.
]]></description>
<dc:creator><![CDATA[ Finlay, A., Jones, A., Evans, R., Colombet, Z., Garbutt, J., Maletta, R. M., OFlaherty, M., Toumpakari, Z., Townsend, N., Robinson, E. ]]></dc:creator>
<dc:date>2026-08-03</dc:date>
<dc:identifier>doi:10.64898/2026.07.29.26359233</dc:identifier>
<dc:title><![CDATA[Nutri-Score labelling in the out-of-home food sector: evidence on effectiveness from a large, randomised control trial in UK restaurant settings]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.01.26359468v1?rss=1">
<title>
<![CDATA[
Bringing public attention to disease into global health priority-setting 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.01.26359468v1?rss=1
</link>
<description><![CDATA[
BackgroundA central concern in global health priority-setting is whether the supply of scientific knowledge aligns with health needs and demands. This alignment is usually assessed by comparing research effort with disease burden, overlooking other type of "social demand" of disease, in particular whether diseases are socially visible and generate public attention. We develop an analytical framework that treats public attention and epidemiological burden as complementary dimensions of health demand and examines their alignment with knowledge supply.

MethodsWe combine data on publications indexed in OpenAlex, disability-adjusted life years from the Global Burden of Disease, and Wikipedia pageviews for 2016 to 2023, as indicators of research effort, disease burden, and public attention, respectively. We map 19 disease groups and 138 specific diseases across these three dimensions. Ternary plots are used to position diseases according to their relative balance across dimensions and to identify diseases that are over- or under-represented in research effort relative to epidemiological burden and public attention. We compare Global North-South patterns using German, Persian, Swahili, and Vietnamese language areas to assess how these relationships vary across territories.

ResultsThe three dimensions show limited alignment. At the disease group level, cardiovascular diseases account for the largest share of disease burden, mental disorders attract the largest share of public attention, and neoplasms concentrate the largest share of research effort. Public attention and disease burden are weakly correlated at both group and specific disease levels, indicating that Wikipedia pageviews and DALYs capture distinct dimensions of health demand. Ternary plots reveal different forms of misalignment, with some diseases showing plots dominated by burden, others by research effort, and others by public attention. Territorial analyses add a further layer by showing that diseases follow disparate patterns of supply-demand (mis)alignment across different linguistic territories.

ConclusionsPublic attention provides a complementary dimension for mapping global health needs and demands. Our approach identifies where scientific knowledge supply fails to match epidemiological and/or public attention, supporting more nuanced global health analysis that may be useful for priority-setting.
]]></description>
<dc:creator><![CDATA[ Arroyo-Machado, W., Rafols, I., Diaz-Faes, A. A. ]]></dc:creator>
<dc:date>2026-08-05</dc:date>
<dc:identifier>doi:10.64898/2026.08.01.26359468</dc:identifier>
<dc:title><![CDATA[Bringing public attention to disease into global health priority-setting]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.03.26359585v1?rss=1">
<title>
<![CDATA[
The association between likely ADHD and autism, and not being in employment, education, or training: a frequency-matched case-control study in working-age adults in the UK 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.03.26359585v1?rss=1
</link>
<description><![CDATA[
BackgroundTo estimate the frequency of likely, often undiagnosed autism and attention deficit hyperactivity disorder (ADHD) in UK adults of working age (18-66 years) who are not in education, employment, or training (NEET), and to examine whether neurodivergent traits are associated with NEET status directly and indirectly via health burden and educational attainment.

DesignFrequency-matched online case-control study.

SettingUK general population, recruited via online research platform Prolific.

ParticipantsSix hundred adults of working age (18-66 years); 300 NEET, 300 in education, employment, or training (EET) matched at the marginal level on age, sex assigned at birth, and ethnicity.

Primary and secondary outcome measuresAutistic traits (Ritvo Autism and Asperger Diagnostic Scale-14, RAADS-14) and ADHD traits (Adult ADHD Self-Report Scale, ASRS-5) indexed likely autism and ADHD (cut-off [&ge;]14 on each). Physical and mental health conditions were self-reported and aggregated into composite indices of health burden. NEET status was the primary outcome; educational attainment and health burden were tested as parallel mediators of the association between neurodivergent traits and NEET status.

ResultsNEET participants screened positive more frequently for likely autism (66.3% vs 49.0%; OR 2.05, 95% CI 1.48 to 2.85) and likely ADHD (34.3% vs 26.0%; OR 1.46, 95% CI 1.03 to 2.08) than EET participants, despite identical existing formal diagnosis rates. Physical (OR 2.00, 95% CI 1.38 to 2.90) and mental (OR 2.57, 95% CI 1.80 to 3.68) health conditions were also associated with higher odds of NEET status. In mediation analyses, neurodivergent traits predicted NEET status both directly (OR 1.33, 95% CI 1.13 to 1.68) and indirectly via greater health burden (indirect OR 1.13, 95% CI 1.02 to 1.35) and lower educational attainment (indirect OR 1.08, 95% CI 1.03 to 1.15).

ConclusionNEET adults showed a marked excess of autism and ADHD traits, alongside elevated physical and mental health burden and lower educational attainment. Earlier recognition of neurodivergent traits, proactive provision of equitable requirements in education and employment, and integrated physical and mental health support may reduce NEET risk in this population. This has considerable implications for policy and practice in health, education, and wider society.
]]></description>
<dc:creator><![CDATA[ Quadt, L., Russell, E., Green, J., Joynson, E., Jones, B., Müller-Sedgwick, U., Davidson, C., Critchley, H., Eccles, J. ]]></dc:creator>
<dc:date>2026-08-07</dc:date>
<dc:identifier>doi:10.64898/2026.08.03.26359585</dc:identifier>
<dc:title><![CDATA[The association between likely ADHD and autism, and not being in employment, education, or training: a frequency-matched case-control study in working-age adults in the UK]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.07.26359950v1?rss=1">
<title>
<![CDATA[
Measuring implementation of clinical guidelines through the COVID-19 pandemic, using linked national health records: a national study of type 2 diabetes in England 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.07.26359950v1?rss=1
</link>
<description><![CDATA[
ObjectivesTo examine the conformance to type 2 diabetes NICE guidelines across cardiovascular risk strata; and to quantify geographical variation in treatment pathways following the COVID-19 pandemic, encompassing guideline changes.

DesignWe carried out a retrospective observational study using linked electronic health records across England. Process mining, a data driven method that can reconstruct clinical treatment pathways, was applied to map 12-month treatment trajectories after treatment initiation. Conformance with NICE NG28 (2022) was quantified using a structural similarity index. Further, behavioural and entropy-based similarity (capturing treatment variability and complexity) measures were used to assess sequencing and heterogeneity of treatment.

SettingPrimary and secondary care in England datasets within the National Health Service England Secure Data Environment (NHSE SDE), analysed first at national level and then across 42 Integrated Care Boards (ICBs) which are the devolved health care geographical delivery regions in England.

Participants822,650 individuals with newly diagnosed T2DM between 1-February-2022 and 1-November-2025, stratified into low cardiovascular risk (LR-C; QRISK3<10), high risk (HR-C; QRISK3>=10 or receiving statins/blood pressure lowering treatment), and established cardiovascular disease (eCVD-C). Participants were followed for 12 months after first dispensed glucose lowering therapy.

Main outcome measureFirst line therapy, treatment intensification and switching within 12 months; change in glycated haemoglobin (HbA1c); quantified conformance to NICE recommended pathways; and regional variation in broader similarity measures.

ResultsMetformin monotherapy was the dominant initiation strategy in LR-C and HR-C cohorts (92.4% and 90.2%, respectively), whereas eCVD-C showed lower uptake of metformin (68.9%) and higher uptake of SGLT2 inhibitors (26.3%). Intensification from metformin to combination therapy was infrequent across all cohorts (<1%), although HR-C demonstrated the highest treatment transitions and switching behaviour. Dispensed SGLT2 inhibitor use was nearly threefold higher in eCVD-C (26.7%) than in LR-C (9.0%) or HR-C (10.7%). Overall, conformance to NICE-recommended pathways remained modest nationally, particularly in LR-C and HR-C. Across 42 ICBs, substantial regional heterogeneity in treatment pathways and guideline conformance was observed, with conformance ranging from 0.29 to 1.00 in LR-C pathways, 0.40 to 1.00 in HR-C pathways, and 0.54 to 0.92 in eCVD pathways.

ConclusionNational T2DM treatment pathways for post-pandemic showed higher alignment to NICE guidelines in eCVD-C compared to the other risk groups, with ongoing gaps and large regional variations in other risk groups. Process mining offers a scalable approach to monitor implementation of guideline recommended care that could support learning health systems. Using T2DM during and post COVID-19 pandemic as a case study, this work demonstrates how these methods can assess the use of existing and innovative therapies, identify gaps and guide future adoption to ensure recommended treatments reach the right patient groups.
]]></description>
<dc:creator><![CDATA[ Biglarbeigi, P., Dale, C., Lambarth, A., Mason, A., Takhar, R., Ballabio, G., Minshull, J., Mamas, M. A., Tomlinson, C., Rowark, S., Rayman, G., Pearson, E. R., Khunti, K., Sattar, N., Sofat, R., the CVD-COVID-UK/CVD-IMPACT Consortium ]]></dc:creator>
<dc:date>2026-08-11</dc:date>
<dc:identifier>doi:10.64898/2026.08.07.26359950</dc:identifier>
<dc:title><![CDATA[Measuring implementation of clinical guidelines through the COVID-19 pandemic, using linked national health records: a national study of type 2 diabetes in England]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-11</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.13.26360377v1?rss=1">
<title>
<![CDATA[
Evolving priorities in malaria research in Indonesia (2015-2025): A scoping review and bibliometric analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.13.26360377v1?rss=1
</link>
<description><![CDATA[
BackgroundMalaria remains a major public health challenge in Indonesia, with transmission concentrated in several eastern regions. A systematic overview of national research activity is needed to show how scientific priorities have changed and whether the evidence base is aligned with elimination needs.

Methodology/Principal findingsWe conducted a scoping review and bibliometric analysis of Scopus-indexed malaria publications from 2015 to 2025 following PRISMA-ScR guidance. Records were screened for an Indonesian institutional affiliation or an explicit Indonesia-specific study component. Publication trends, co-authorship, keyword networks, citation patterns, thematic evolution, and exploratory forecasts were analysed. Keyword text was represented using term frequency-inverse document frequency and grouped with K-means clustering. The initial candidate set contained 592 publications; four false-positive records were excluded, leaving 588 eligible Indonesia-related publications. Of these, 583 had an Indonesian affiliation identifiable in the exported Scopus metadata and 586 had usable keyword metadata for thematic analysis. Ten clusters were identified. Environmental and Community-Based Studies was the largest theme (110/586, 18.77%), followed by Plasmodium Species and Clinical Parasitology (85/586, 14.51%), Molecular Diagnostics (76/586, 12.97%), Treatment and Antimalarial Drugs (69/586, 11.77%), and Health Systems and Malaria Control Programs (67/586, 11.43%). Treatment-related research had the greatest total and mean citation impact. Publication output accumulated continuously without a clear plateau. Forecasts suggested the strongest continued growth in environmental and community-based research, while treatment and health-system themes were comparatively stable.

Conclusions/SignificanceIndonesian malaria research became more diverse while retaining strong clinical and treatment foundations. Future research planning should balance biomedical priorities with environmental, community, diagnostic, and implementation research. Forecasts are exploratory and should not be interpreted as precise predictions.

Author summaryMalaria remains a major health problem in parts of Indonesia, especially in eastern provinces. We examined how malaria research related to Indonesia changed between 2015 and 2025. We reviewed 588 eligible publications indexed in Scopus and used publication records, author links, keywords, citations, and annual trends to identify the main areas of research. We found that research output increased overall but varied considerably from year to year. Clinical studies of malaria parasites and antimalarial treatment remained important, while environmental and community-based research became the largest area. Molecular diagnostic and genetic studies also attracted substantial scientific attention. Research using artificial intelligence was present but still formed only a small part of the overall evidence base. Our exploratory forecasts suggest that environmental and community research may continue to grow most strongly, whereas treatment and health-system research may remain relatively stable. These findings show that malaria research related to Indonesia has become more diverse rather than reaching a stable or mature endpoint. We believe that future planning should maintain strong clinical and treatment research while giving greater attention to environmental conditions, community participation, diagnostic implementation, and health-system needs that directly support malaria elimination.
]]></description>
<dc:creator><![CDATA[ Setiawan, B., Cooper, J. M., Reboud, J. ]]></dc:creator>
<dc:date>2026-08-17</dc:date>
<dc:identifier>doi:10.64898/2026.08.13.26360377</dc:identifier>
<dc:title><![CDATA[Evolving priorities in malaria research in Indonesia (2015-2025): A scoping review and bibliometric analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.17.26360374v1?rss=1">
<title>
<![CDATA[
Developing a needs-based workforce plan for audiology services in England 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.17.26360374v1?rss=1
</link>
<description><![CDATA[
BackgroundInternationally, healthcare workforce planning models are focussed on balancing supply and demand, rarely addressing factors such as demographic shifts and evolving health needs. For audiology services, there is a clear imperative for improved workforce planning to ensure adequate staff numbers to deliver services safely and effectively. However there is still no consensus on safe minimum staffing levels or the optimal skill mix for high-quality audiology services.

MethodsThis research aimed to estimate the audiology health service workforce requirements in England, to meet current and projected 5 and 10 year demand for services, based on population changes and anticipated changes in demand. Informed by key stakeholders, a needs-based model was developed by (1) analysing NHS Englands National Data Collection for Audiology Services dataset to determine current workforce, (2) creating an epidemiological model to predict changes in service population over next 5 and 10 yrs, and (3) using audiology professional body endorsed estimates on East of England staff grade required per activity.

This research aimed to establish markers of quality in audiology service provision and estimate the audiology workforce requirements to meet current and projected demand for services, based on population changes and anticipated changes in demand. Following stakeholder engagement, a needs-based model was developed by (1) analysing National Data Collection for Audiology Services dataset to determine current workforce, (2) creating an epidemiological model to predict changes in service population over next 5 and 10 yrs (3) use of BAA endorsed estimates delivered in East of England on staff grade required per activity.

ResultsThe estimates for 10-year adult and paediatric audiology service whole time equivalent (WTE) safe minimum staffing levels for England (bands 2-7, current waiting times maintained) based on a population change model (Model 1), and two further models for paediatrics specifically (Model 2 and Model 3) were as follows: for adult audiology Model 1 estimates a 7.40% increase by 2035 (to 1125.18 WTE). For paediatric audiology Model 1 estimates a -6.3% (to 593.47 WTE) decrease due to underlying paediatric population decline in England, whereas the case complexities considered in Model 2 (1072.33 WTE) and Model 3 estimate a 10-year increase of 71.23% (to 1072.33 WTE) and 59.17% (to 996.82 WTE) respectively.

ConclusionsThis is the first study to conduct a needs-based assessment of workforce requirements for UK audiology services and shows a substantial need to increase the audiology workforce. Investment in audiology workforce recruitment and training is essential to ensure that future activity levels meet population needs and that quality care is delivered. Consideration of changing demographics is required for planning future workforce specialisation. Further analysis to address workforce equity, the impact of changes in skill mix and service delivery models and local area demographics/prevalence variation is required alongside potential efficiencies.
]]></description>
<dc:creator><![CDATA[ Rajasingam, S., MacDonald, P., Sethi, J., Taylor-Gonzalez, A., Hall, A., Meyenburg, I. ]]></dc:creator>
<dc:date>2026-08-20</dc:date>
<dc:identifier>doi:10.64898/2026.08.17.26360374</dc:identifier>
<dc:title><![CDATA[Developing a needs-based workforce plan for audiology services in England]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-20</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.19.26360842v1?rss=1">
<title>
<![CDATA[
Regulation-Driven Variation in Utilization and Cost of B-Cell Depleting Therapies for Multiple Sclerosis: A Cross-National Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.19.26360842v1?rss=1
</link>
<description><![CDATA[
BackgroundRituximab and ocrelizumab target the same CD20 receptor. Rituximab is off-patent and prescribed off-label; ocrelizumab is licensed and patent-protected. Whether the resulting differences in utilization and cost reflect clinical value or regulatory structure has not been examined.

ObjectiveTo determine whether utilization and cost of B-cell depleting therapy across six health systems track regulatory approval status more closely than comparative effectiveness.

MethodsWe examined rituximab and ocrelizumab utilization and cost in Sweden, France, Germany, the United Kingdom, Italy and the United States (2016-2024). Costs were drawn from published national sources on a consistent ex-factory basis. Utilization was registry-measured for Sweden, France and Germany, measured from national claims for the United States, and estimated from indirect data for the United Kingdom and Italy. Weighted annual costs per patient on B-cell depleting therapy were modeled by Monte Carlo simulation (10,000 iterations).

ResultsRituximab constituted the near-totality of B-cell depleting therapy in Sweden but 2.3% to 18.7% of use in the other five systems. Mean annual cost per patient ranged from $3,014 (Sweden) to $52,506 (United States), a 17-fold difference, with the four other European systems between $18,140 and $26,262. Adopting Swedens utilization pattern was associated with modeled five-year per-patient differences in drug acquisition cost of $76,000 to $248,000.

ConclusionUtilization and cost align more closely with regulatory approval status than with available effectiveness data. International reference pricing acts on the price of the licensed agent but leaves intact the regulatory asymmetry that determines which agent is prescribed.

PrecisRituximabs share of anti-CD20 use in multiple sclerosis, and its cost, track national off-label reimbursement rules rather than comparative effectiveness, across six high-income health systems.

HighlightsWhat is already known. Rituximab and ocrelizumab deplete the same B-cell population, and a phase 3 randomized trial has now reported rituximab non-inferior to ocrelizumab on the primary radiological endpoint. Rituximab is off-patent and prescribed off-label; ocrelizumab is licensed and patent-protected. Whether the large international differences in which agent is used, and at what cost, reflect clinical value or regulatory structure had not been examined.

What this study adds. Across Sweden, France, Germany, the United Kingdom, Italy and the United States, rituximabs share of anti-CD20 use ranged from 96% to 2.3% and mean annual cost per treated patient from $3,014 to $52,506. Because United States and Swedish ex-factory prices differ by the same 2.80-fold for both drugs, the cost gap separates exactly into a price component and a utilization component.

What it means for decision making. Utilization tracked national off-label reimbursement rules rather than comparative effectiveness or price. Adopting Swedens utilization pattern corresponds to modeled five-year drug-acquisition differences of $76,000 to $248,000 per patient. International reference pricing acts on the price of the licensed agent and leaves the regulatory asymmetry intact, so measures that change which agent may be reimbursed, such as treatment compendia and off-label outcome tracking, are the operative levers.
]]></description>
<dc:creator><![CDATA[ Streicher, N. S., Angell, T. ]]></dc:creator>
<dc:date>2026-08-25</dc:date>
<dc:identifier>doi:10.64898/2026.08.19.26360842</dc:identifier>
<dc:title><![CDATA[Regulation-Driven Variation in Utilization and Cost of B-Cell Depleting Therapies for Multiple Sclerosis: A Cross-National Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.19.26360851v1?rss=1">
<title>
<![CDATA[
Comparing HIV Testing Patterns Among Adolescent Girls, Young Women, and Older Women in Nigeria: A Comparative Analysis and Socioecological Correlates 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.19.26360851v1?rss=1
</link>
<description><![CDATA[
BackgroundHIV testing is a key entry point for prevention and treatment in Nigeria, yet age-related disparities persist. Adolescent girls and young women (AGYW) are disproportionately affected by HIV but often demonstrate lower uptake of testing services. This study examined differences in HIV self-testing awareness, use, and antenatal HIV testing between AGYW and older women, the distribution of HIV testing service uptake, and identified multilevel factors associated with HIV self-test awareness and testing among AGYW.

MethodsThis study analyzed cross-sectional data from the 2023-2024 Nigeria Demographic and Health Survey (NDHS), including women aged 15-49 years. Descriptive statistics were used to assess differences in HIV self-testing awareness, use, antenatal HIV testing, and place of HIV testing between Adolescent Girls and Young Women (AGYW) (15-24 years) and older women (25-49 years). Among AGYW, bivariate and multivariate logistic regression were conducted to identify socioecological factors associated with HIV self-testing, awareness and use.

ResultsA total of 14,708 AGYW and 24,342 older women were included in the analysis. The median age of AGYW was 19 years (IQR: 17-22), compared to 35 years (IQR: 25-41) among older women. Older women reported significantly higher awareness of HIV self-testing (13.1%) compared to AGYW (8.8%). Use of the HIV self-testing kit was low overall but higher among older women (2.3%) than among AGYW (1.1%). Older women reported greater uptake of antenatal HIV testing (57.9%) than AGYW (48.4%). Education, wealth, and internet use were positively associated with awareness, while AGYW aged 15-19 had significantly lower odds of awareness than AGYW women aged 20-24. Regional disparities were also observed in the awareness and use of HIV self-test kits.

ConclusionsFindings support that targeted, AGYW-centred strategies are needed to improve equitable access to HIV testing and achieve national and global HIV prevention goals.
]]></description>
<dc:creator><![CDATA[ Akinwande, S. F., Akinwande, K. O., Logie, C. H., Massaquoi, N., Okungbowa, O. J. ]]></dc:creator>
<dc:date>2026-08-25</dc:date>
<dc:identifier>doi:10.64898/2026.08.19.26360851</dc:identifier>
<dc:title><![CDATA[Comparing HIV Testing Patterns Among Adolescent Girls, Young Women, and Older Women in Nigeria: A Comparative Analysis and Socioecological Correlates]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1?rss=1">
<title>
<![CDATA[
Development of a high-alert medicines list and pilot testing of error prevention strategies in Sri Lanka: a cross-sectional mixed methods study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1?rss=1
</link>
<description><![CDATA[
High-alert medicines (HAM) cause preventable harm. This study aimed to develop a national HAM list and corresponding error prevention strategies (EPS) for hospital and community pharmacy settings in Sri Lanka. A mixed-methods cross-sectional observational study was conducted. Potential HAM were identified through an interviewer-administered questionnaire completed by 315 pharmacists from government (n=155) and private (n=160) sectors. Concurrently, a research pharmacist documented HAM-related problems and errors over three years. Additional HAM were identified by reviewing the Institute for Safe Medication Practices (ISMP) HAM list. A draft HAM list was refined and validated during five national stakeholder meetings convened by the Directorate of Healthcare Quality and Safety, Ministry of Health, Sri Lanka, involving 62 multidisciplinary stakeholders. These medicines were categorized using the A-PINCH (O) framework. EPS were developed through literature review and pilot-tested at a tertiary care hospital in Colombo. Key strategies included red-colour labelling, HAM stickers, separate storage, enhanced counselling, improved labelling, and patient information leaflets in Sinhala and Tamil for ten prioritised medicines. Feasibility was evaluated one year post-implementation using a questionnaire and three focus group discussions among hospital pharmacists (n=45). Quantitative data were analysed descriptively and qualitative data thematically. HAM identification differed by source: pharmacists (n=43), research pharmacist (n=40), ISMP list (n=80), and stakeholders (n=20). The validated list included 100 HAM for acute care settings, mainly injectable medicines, and 40 HAM for community settings, predominantly oral medicines. Awareness of the HAM list was 95.6% following implementation. Self-reported adherence to EPS, use of HAM labels and stickers, and availability of patient information leaflets were each 100%. Overall, 93.2% of pharmacists reported counselling patients on HAM requiring special instructions. Five themes emerged: usefulness, content adequacy, EPS implementation, operational barriers, and recommendations. National HAM lists for acute care and community settings were successfully developed. Pilot-tested EPS demonstrated high feasibility and acceptability, supporting national implementation and informing MOH policy through an official circular.
]]></description>
<dc:creator><![CDATA[ Bandara, G. R. W. S. K., Samaranayake, N., Ranaweera, D., Samaranayake, D., Galappatthy, P. ]]></dc:creator>
<dc:date>2026-08-28</dc:date>
<dc:identifier>doi:10.64898/2026.08.24.26361195</dc:identifier>
<dc:title><![CDATA[Development of a high-alert medicines list and pilot testing of error prevention strategies in Sri Lanka: a cross-sectional mixed methods study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-28</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.23.26361157v1?rss=1">
<title>
<![CDATA[
Emotional intelligence and the perception of good leadership in healthcare: a mixed-methods study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.23.26361157v1?rss=1
</link>
<description><![CDATA[
ObjectiveTo identify and rank the leadership traits most valued by medical staff in public hospitals, and to compare them with an established generic instrument and a generative artificial intelligence (AI) source.

DesignSequential exploratory qualitative-quantitative (QUAL-QUAN) mixed-methods study: focus groups followed by an online ranking survey, with cross-comparison against the Northouse Leadership Traits Questionnaire (LTQ) and a ChatGPT-derived list (LAIT).

SettingMajor public hospital affiliated with Monash University, Melbourne, Australia, in 2023.

ParticipantsTwenty-four senior medical staff (16 men, 8 women; 18 clinicians, 6 administrators) recruited through opportunistic sampling.

Main outcome measuresWeighted ranking of the ten most desired leadership traits (Leadership Enabling Traits Survey, LETS); internal consistency (Cronbachs ); agreement between LETS and LTQ self-scores; and strong overlap with the AI-derived list.

ResultsThe first most-weighted LETS traits were integrity (1.526), communication (1.435), compelling vision (1.404), emotional intelligence (1.040) and empathy (0.969) - the same five identified by the AI source. Integrity was weighted 3.6 times more heavily than rebelliousness (0.424). Both LETS and LTQ achieved Cronbachs  >0.7. Unweighted total self-scores did not differ between LETS (77.4{+/-}7.6) and LTQ (78.4{+/-}6.9); weighted emotional intelligence related and other-trait sub-scores diverged significantly (p<0.001). Survey power was 45% at =0.05.

Summary BoxO_ST_ABSWhat this paper addsC_ST_ABSWhat is already known on this topicO_LIEmotional intelligence (EI) is consistently identified as an important attribute of effective healthcare leaders, and a range of generic leadership instruments are available (e.g. Northouses LTQ).
C_LIO_LILeadership-selection criteria in healthcare have historically been derived top-down from organisational, regulatory or academic frameworks rather than from the views of the clinicians who must follow those leaders.
C_LIO_LIExisting instruments treat candidate leadership traits as equally weighted, even though clinical leaders intuitively rank some attributes (e.g. integrity) far above others.
C_LI

What this study addsO_LI10-item, follower-derived, weighted Leadership Enabling Traits Survey (LETS) instrument was developed from focus groups with senior medical staff and ranked by survey, providing an empirically-weighted alternative to existing equally-weighted tools.
C_LIO_LItop five LETS traits (integrity, communication, vision, emotional intelligence, empathy) matched the unprompted top five traits generated by a contemporary large-language model (LAIT), suggesting that EI-related attributes are a stable feature of leadership representations in both human and machine-generated sources.
C_LIO_LIempirically-derived weights revealed material divergence between context-specific (LETS) and generic (LTQ) instruments when EI-related and non-EI traits were considered separately, supporting the case for situation-specific leadership tools rather than universal scoring.
C_LI
]]></description>
<dc:creator><![CDATA[ Wilson, J. W., Michaelis, A., Miller, M.-E. ]]></dc:creator>
<dc:date>2026-08-29</dc:date>
<dc:identifier>doi:10.64898/2026.08.23.26361157</dc:identifier>
<dc:title><![CDATA[Emotional intelligence and the perception of good leadership in healthcare: a mixed-methods study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.25.26361308v1?rss=1">
<title>
<![CDATA[
When Data Reform Meets Bureaucratic Hierarchy: A Political Economy Analysis of Institutionalizing a District Health Data Bank in West Sumbawa District, Indonesia 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.25.26361308v1?rss=1
</link>
<description><![CDATA[
BackgroundAlthough often perceived as a technical tool, a data bank is fundamental for district performance management, facilitating integrated coordination, data consolidation, and routine information use for decision-making. However, implementation unfolds within hierarchical bureaucratic systems shaping authority distribution, workload allocation, coordination, and resource use. This study examines the political economy of institutionalizing a district-level health data bank in West Sumbawa District, Indonesia.

MethodA longitudinal qualitative case study was conducted in West Sumbawa District, West Nusa Tenggara Province, Indonesia, from November 2025 to March 2026 across three evaluation phases (baseline, midline, endline), involving 25 District Health Office (DHO) officers appointed to the Health Data Bank team, representing five organizational units, including the Secretariat, General and Human Resources Unit, and Public Health Division. Data were collected through participatory workshops, focus group discussions, in-depth interviews, observation, and document review, including official decrees, SOPs, meeting minutes, and implementation records, and analysed using Bosserts Decision Space Framework combined with a problem-driven political economy analysis examining how power relations, institutional norms, workload, resource support, and perceived incentives influenced whether technical reforms became operationalized in routine practice.

ResultsThe Health Data Bank progressed from strong institutional acceptance to structural formalization. Decision-making authority remained centralized within the Secretariat, enabling coordination but limiting distributed ownership. Resource constraints increased workload, concentrated in the Secretariat and division coordinators responsible for data consolidation and validation, without dedicated financing or staffing, despite improved analytical capacity. Accountability mechanisms were established through governance instruments, though enforcement and feedback loops remained underdeveloped. Data submission, validation, and use were not yet fully institutionalized, resulting in a gap between structural readiness and functional use.

ConclusionData institutionalization involves both technical and organizational processes, requiring collaborative negotiation of authority, workload, and resources. Continued attention to these factors will help structural formalization translate into sustainable operational outcomes.
]]></description>
<dc:creator><![CDATA[ Asrullah, M., Ati, A. W., Fortunandha, D. K., Janitra, G. F., Setiawan, E., Mulyadita, U., Pratiwi, A., Dewi, S. L., Boxshall, M. ]]></dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.25.26361308</dc:identifier>
<dc:title><![CDATA[When Data Reform Meets Bureaucratic Hierarchy: A Political Economy Analysis of Institutionalizing a District Health Data Bank in West Sumbawa District, Indonesia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.26.26361003v1?rss=1">
<title>
<![CDATA[
Integrated MB-PhD training is a long-term investment in the clinician-scientist workforce 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.26.26361003v1?rss=1
</link>
<description><![CDATA[
BackgroundClinician-scientists translate clinical observation into discovery, trials, and policy, yet this workforce is shrinking across health systems worldwide. Integrated MB-PhD training, pausing medical training to complete a PhD before clinical exposure or specialisation, is one route into this career. We aimed to evaluate the long-term value of MB-PhD training and the barriers to clinical-academic careers faced after graduation.

MethodsWe evaluated all 131 graduates (29.8% female) who entered the University College London (UCL) MB-PhD programme over a 25-year period (1994-2018). Bibliometric outputs were collated via an inter-linked information system. Concurrently, all 131 graduates were invited to respond to open-ended questions on career benefits and structural barriers; 99 (75.6%) responded, and responses were independently coded into themes, which were then reviewed and confirmed by a Study Group of 107 individuals, including the 91 respondents who agreed to participate further.

ResultsGraduates produced 5,877 publications (1,141 first-author, 819 corresponding-author), attracting 350,754 citations, with a mean relative citation ratio of 3.30 {+/-} 0.47, approximately three times the field average and sustained across three decades of programme entry. Graduates secured an estimated $157.55 million across 99 grants, released 465 public datasets, and were named investigators on 31 clinical trials across five continents. Among the 99 survey respondents, 49.5% held consultant-grade posts, 72.7% remained research-active, and 25.3% had reached senior academic grade. Openended responses were coded into five recurring structural barriers, subsequently confirmed by the Study Group: insufficient protected research time (72.2% of responses), unsupportive training structures and limited career opportunities (36.7%, 24.4% of responses), funding and pay barriers (22.2% of responses), and lack of mentorship or geographical/family constraints (14.4%, 13.3% of responses).

ConclusionsIntegrated MB-PhD training generates sustained academic productivity and leadership, but structural barriers threaten retention of graduates within clinical-academic careers. Protecting research time, stabilising funding and pay, and reducing geographic instability, amongst other interventions, are needed to retain the clinician-scientists that health systems have already invested in training.
]]></description>
<dc:creator><![CDATA[ Jafree, D. J., Sun, M., Stewart, G. W., Gishen, F., Swanton, C., Motallebzadeh, R., the UCL MB-PhD Outcomes Study Group ]]></dc:creator>
<dc:date>2026-09-03</dc:date>
<dc:identifier>doi:10.64898/2026.08.26.26361003</dc:identifier>
<dc:title><![CDATA[Integrated MB-PhD training is a long-term investment in the clinician-scientist workforce]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.28.26361597v1?rss=1">
<title>
<![CDATA[
Policy implementation gap: a qualitative evaluation of the implementation of Ghanas national cancer control strategy 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.28.26361597v1?rss=1
</link>
<description><![CDATA[
BackgroundCancer is a growing public health challenge in Ghana, with 27,385 new cases and 17,944 deaths recorded in 2022. Ghana developed a National Cancer Control Strategy (NCCS) in 2011 to guide prevention, early detection, treatment, and palliative care. The strategy expired in 2016 and has not been formally evaluated or renewed, leaving cancer control efforts without a guiding policy framework for nearly a decade. This study examined how the strategy was implemented, what barriers were encountered and what stakeholders recommend for a strengthened national cancer response.

MethodsWe conducted a qualitative descriptive study using semi-structured key informant interviews. Fifteen participants were recruited through purposive sampling, supplemented by snowball referrals, representing three groups: Ministry of Health policymakers, frontline healthcare providers and representatives of cancer-focused non-governmental organisations. Data were collected between June and September 2025 and analysed using Braun and Clarkes six-phase thematic analysis framework, guided deductively by the WHO Health Systems Building Blocks framework

ResultsThree themes emerged: NCCS interventions and systems implemented, capturing progress in cancer awareness, HPV vaccination and pilot screening programmes alongside persistent geographic and financial inequities in access; barriers to implementation, including inadequate financing, infrastructure and workforce shortages, the absence of a national cancer registry and governance failures, among them the finding that no frontline healthcare provider interviewed had any awareness of the NCCS; and recommended implementation strategies, including co-production of a renewed strategy, establishment of a dedicated National Cancer Control Programme, expanded health insurance coverage and decentralisation of oncology services.

ConclusionThe NCCS was not operationally embedded in the health system. The evidence points to failures in policy dissemination as a constraint that precedes resource constraints. Addressing Ghanas rising cancer burden requires renewed political commitment, co-produced governance structures and accountability mechanisms. These findings have relevance for other low- and middle-income country settings facing similar challenges.
]]></description>
<dc:creator><![CDATA[ Bashiru, J., Baatiema, L. ]]></dc:creator>
<dc:date>2026-09-03</dc:date>
<dc:identifier>doi:10.64898/2026.08.28.26361597</dc:identifier>
<dc:title><![CDATA[Policy implementation gap: a qualitative evaluation of the implementation of Ghanas national cancer control strategy]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.18.26363419v1?rss=1">
<title>
<![CDATA[
Clinical Trial Components of NIH Career Development Awards: Supporting the Nation's Future Trialists 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.18.26363419v1?rss=1
</link>
<description><![CDATA[
In 2027, the National Institutes of Health (NIH) will no longer support costs associated with clinical trials (CT) for career development (K) awards. NIHs CT definition encompasses many types of research, from early-stage pilot work through definitive studies. The types and sizes of trials K awardees conduct have not been described, which could inform ongoing policy changes relevant to the next generation of clinical trialists. We conducted a cross-sectional analysis of NIH RePORTER data to characterize the types and sizes of CTs supported by NIH K01, K08, and K23 awards funded in fiscal years 2024-2025 under a CT Required or CT Optional funding opportunity announcement (FOA), with non-missing abstract text. A rule-based classification scheme applied to free-text abstracts categorized each award into 5 mutually exclusive trial types: pilot/feasibility/proof-of-concept, efficacy/effectiveness, trial confirmed with type unclear, other (mechanistic, ancillary, or phase I/II), or no trial-specific language identified. Trial size was assessed among abstracts reporting an explicit, manually verified sample size. Of 1336 unique awards funded under CT Required (n=1051) or CT Optional (n=285) FOAs, 815 (61.0%) were classified as pilot, feasibility, or proof-of-concept studies, and 55 (4.1%) as efficacy or effectiveness studies; 204 (15.3%) had a confirmed trial of unclear type, 41 (3.1%) were other, and 221 (16.5%) had no trial-specific language. Among CT Required awards, 730 (69.5%) were pilot, feasibility, or proof-of-concept work. Among 273 awards (20.4%) with a verified sample size, the median was 60 participants (IQR, 44-80), with 236 (86.4%) enrolling [&le;]100 participants. Given these findings that CT within NIH K awards are generally small and early-stage, NIHs decision to no longer support trial costs may adversely affect the scientist development pipeline.
]]></description>
<dc:creator><![CDATA[ Derington, C. G., Cervantes, L., Allen, L. A., Trinkley, K. E., Huebschmann, A. G., Ho, P. M. ]]></dc:creator>
<dc:date>2026-09-20</dc:date>
<dc:identifier>doi:10.64898/2026.09.18.26363419</dc:identifier>
<dc:title><![CDATA[Clinical Trial Components of NIH Career Development Awards: Supporting the Nation's Future Trialists]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-20</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.17.26363313v1?rss=1">
<title>
<![CDATA[
Examining the Appeal of Cigarette Filters: An Online Randomised Experiment Among Adults in Great Britain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.17.26363313v1?rss=1
</link>
<description><![CDATA[
Background and aimsCigarette filters are present in almost all cigarettes sold globally, despite providing no health protection and contributing substantially to environmental pollution. Filters may also increase cigarette appeal and reinforce misperceptions of reduced harm. This study aimed to examine the impact of cigarette filters on cigarette appeal and perceptions of health and environmental harms among adults in Great Britain.

DesignOnline between-subject randomised experiment embedded within a nationally representative survey.

SettingGreat Britain, May 2026.

ParticipantsAdults aged 18+ years, recruited through the YouGov Social Omnibus survey (n=3961). Subgroup analyses were conducted among people who currently smoked (n=499) and people who smoked daily (n=270).

Intervention and comparatorParticipants were randomised to view images of cigarettes either without filters (intervention) or with filters (conventional cigarettes; comparator).

MeasurementsThe primary outcome was selecting one of the displayed cigarettes to smoke vs. selecting none. Secondary outcomes were perceptions that the cigarette was extremely harmful to health and extremely harmful to the environment. Logistic regression models were used, adjusting for age, sex and smoking status.

ResultsThere was strong evidence to suggest that participants who viewed cigarettes without filters had markedly lower odds of choosing a cigarette to smoke than those who viewed cigarettes with filters (19.1% vs. 28.1%; adjusted odds ratio [AOR]=0.46 [95% confidence interval [CI]=0.38-0.55], p<.001). Cigarettes without filters also had higher odds of being perceived as extremely harmful to health (65.2% vs. 59.9%; AOR=1.26 [1.10-1.45], p=.001). Evidence was insufficient to conclude a difference between conditions in perceiving cigarettes as extremely harmful to the environment (41.8% vs. 44.3%; AOR=0.89 [0.78-1.01], p=.074). Findings were similar among people who currently smoke, with participants who viewed cigarettes without (vs. with) filters having markedly lower odds of choosing a cigarette (67.4% vs. 94.2%; AOR=0.12 [0.06-0.22], p<.001). These findings were also similar among people who smoke daily (70.7% vs. 94.8%; AOR=0.14, 95% CI=0.06-0.36, p<0.001). However, evidence was insufficient to conclude differences in perceived health harms between conditions among people who smoke currently (29.7% vs. 27.8%; p=.588) or daily (32.2% vs. 28.6%; p=.324).

SummaryRemoving cigarette filters reduced the appeal of cigarettes among the general population and people who smoke. Removing filters also increased perceptions of health harms in the general population. Given that cigarette filters provide no health protection and contribute to environmental pollution, policies that regulate or prohibit filters may support public health and environmental goals.
]]></description>
<dc:creator><![CDATA[ East, K., Cheeseman, H., Taylor, E. V. ]]></dc:creator>
<dc:date>2026-09-20</dc:date>
<dc:identifier>doi:10.64898/2026.09.17.26363313</dc:identifier>
<dc:title><![CDATA[Examining the Appeal of Cigarette Filters: An Online Randomised Experiment Among Adults in Great Britain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-20</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
